What is the 13F Pro Quality Score for XFOR?

13F Pro ranks X4 Pharmaceuticals, Inc (XFOR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View XFOR's current score at https://13fpro.ai/company/XFOR (free sign-up required for the full ranking).

Which hedge funds own the most XFOR stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of XFOR include MORGAN STANLEY, FMR, Bain Capital Life Sciences Investors,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/XFOR as soon as new 13F filings post.

Where does 13F Pro source XFOR data?

All X4 Pharmaceuticals, Inc fundamentals and ownership data come directly from SEC EDGAR. X4 Pharmaceuticals, Inc files with the SEC under CIK 1501697. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is XFOR in?

X4 Pharmaceuticals, Inc (XFOR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is XFOR research updated on 13F Pro?

XFOR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

X4 Pharmaceuticals, Inc(XFOR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1501697 XFOR stock profile & AI dashboard →

13F Pro Quality Score

28.0/100

Rank #2,572 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

99.3/100

Profitability

2.3/100

Balance Sheet

3.5/100

Earnings Quality

12.0/100

Free Cash Flow

1.8/100

Institutional Flow

14.3/100

Revenue Scale

2.0/100

Dilution Risk

4.0/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why XFOR Scores 28/100

exact factor attribution · 2026-09-11

XFOR's composite is driven by revenue growth and earnings growth, held back by free cash flow and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.9 pts

99th pct

Earnings growth

+2.3 pts

95th pct

Institutional flow

-1.8 pts

14th pct

Shareholder dilution

-2.3 pts

4th pct

Earnings quality

-3.8 pts

12th pct

Capital efficiency

-4.7 pts

4th pct

Profitability

-7.2 pts

2th pct

Scale

-7.2 pts

2th pct

Free cash flow

-7.2 pts

2th pct

Latest change (2026-08-06): 29 → 27 · ↓ Institutional flow 67→56; despite ↑ Dilution 4→15

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

XFOR Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for X4 Pharmaceuticals, Inc (XFOR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores XFOR at 28.0/100 on a 32-signal composite quality model, placing it at rank #2,572 of 2,962 stocks — the bottom half of the AI-ranked universe. XFOR scores in the top quartile across revenue growth (99.3). Areas of concern include free cash flow (1.8) and revenue scale (2.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), X4 Pharmaceuticals, Inc reports quarterly revenue of $2.4M, net income of $-16.2M. Top institutional holders of XFOR by reported 13-F value include MORGAN STANLEY, FMR, Bain Capital Life Sciences Investors, based on the most recent SEC filings. XFOR trades on the Nasdaq exchange and files with the SEC under CIK 1501697. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XFOR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for X4 Pharmaceuticals, Inc directly from SEC EDGAR. X4 Pharmaceuticals, Inc's 13F Pro composite quality score has ranged between 12 and 46 since 2021, currently 28.0 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about X4 Pharmaceuticals, Inc

Quirks, history, and lore behind XFOR — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Boston, Massachusetts · focused on rare diseases.
2
The Numbers
A small-cap biotech with no approved product revenue yet — it runs on grants, collaborations, and capital raises while burning cash on R&D, as clinical-stage biotechs do.
3
The History
Founded in the 2010s, the company was built around a single biological insight: that blocking a specific chemokine receptor could unlock treatments for conditions with almost no good options.
4
The Secret
Its entire pipeline targets the CXCR4 pathway — a molecular signaling route involved in immune cell trafficking that has been implicated in rare blood disorders and certain cancers.
5
The Lore
Its lead program targets WHIM syndrome — a rare immunodeficiency so uncommon it affects only a few hundred people worldwide — making it a textbook orphan disease play.
6
The Giveaway
The company's name literally contains a nod to its obsession: the "X4" in its identity refers directly to CXCR4, the receptor it has staked its entire scientific existence on.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$2.4M

Net Income

Q2 2026

$-16.2M

ROIC

Q2 2026

-28.4%

D/E Ratio

Q2 2026

0.48

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+150.0% YoY

$6.5MFY 2025

FY22 $0.00FY23 $0.00FY24 $2.6MFY25 $6.5M

Net Income

-111.5% YoY

$-79.2MFY 2025

FY22 $-93.9MFY23 $-101.2MFY24 $-37.5MFY25 $-79.2M

Operating Income

-138.7% YoY

$-86.9MFY 2025

FY22 $-87.6MFY23 $-107.5MFY24 $-36.4MFY25 $-86.9M

EPS (Diluted)

+66.5% YoY

$-1.87FY 2025

FY22 $-1.52FY23 $-17.07FY24 $-5.59FY25 $-1.87

Total Assets

+98.3% YoY

$290.5MFY 2025

FY22 $155.6MFY23 $147.3MFY24 $146.4MFY25 $290.5M

Total Debt

+0.0% YoY

$75.0MFY 2025

FY22 $33.8MFY23 $55.0MFY24 $75.0MFY25 $75.0M

Op. Cash Flow

+34.6% YoY

$-85.6MFY 2025

FY22 $-77.1MFY23 $-96.5MFY24 $-130.9MFY25 $-85.6M

Free Cash Flow

+34.8% YoY

$-85.6MFY 2025

FY22 $-77.2MFY23 $-96.6MFY24 $-131.2MFY25 $-85.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$6.5M +150.0%	$2.6M	$0.00	$0.00	$0.00 -100.0%	$3.0M
Net Income	$-79.2M -111.5%	$-37.5M +63.0%	$-101.2M -7.8%	$-93.9M -5.8%	$-88.7M -42.8%	$-62.1M
Operating Income	$-86.9M -138.7%	$-36.4M +66.1%	$-107.5M -22.8%	$-87.6M -2.9%	$-85.1M -42.1%	$-59.9M
EPS (Diluted)	$-1.87 +66.5%	$-5.59 +67.3%	$-17.07 -1023.0%	$-1.52 +61.9%	$-3.99 -29.1%	$-3.09
Total Assets	$290.5M +98.3%	$146.4M -0.6%	$147.3M -5.4%	$155.6M +32.8%	$117.2M -4.6%	$122.9M
Total Debt	$75.0M +0.0%	$75.0M +36.4%	$55.0M +62.6%	$33.8M -0.4%	$33.9M +2.3%	$33.2M
Operating Cash Flow	$-85.6M +34.6%	$-130.9M -35.6%	$-96.5M -25.2%	$-77.1M -8.7%	$-70.9M -20.5%	$-58.8M
Free Cash Flow	$-85.6M +34.8%	$-131.2M -35.9%	$-96.6M -25.1%	$-77.2M -7.9%	$-71.5M -18.8%	$-60.2M

Get alerted when XFOR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for X4 Pharmaceuticals, Inc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of XFOR

MORGAN STANLEY
$44.2M9,461,279 sh
FMR LLC
$38.9M8,321,657 sh
Bain Capital Life Sciences Investors, LLC
$37.2M7,967,454 sh
PERCEPTIVE ADVISORS LLC
$37.0M7,933,491 sh
Saturn V Capital Management LP
$32.6M6,973,343 sh
Empery Asset Management, LP
$32.4M6,930,591 sh
Deep Track Capital, LP
$27.5M5,878,757 sh
BlackRock, Inc.
$25.9M5,554,906 sh
Kalehua Capital Management LLC
$17.4M3,722,840 sh
VANGUARD CAPITAL MANAGEMENT LLC
$17.4M3,715,859 sh

Fund	Value	Shares
MORGAN STANLEY	$44.2M	9,461,279
FMR LLC	$38.9M	8,321,657
Bain Capital Life Sciences Investors, LLC	$37.2M	7,967,454
PERCEPTIVE ADVISORS LLC	$37.0M	7,933,491
Saturn V Capital Management LP	$32.6M	6,973,343
Empery Asset Management, LP	$32.4M	6,930,591
Deep Track Capital, LP	$27.5M	5,878,757
BlackRock, Inc.	$25.9M	5,554,906
Kalehua Capital Management LLC	$17.4M	3,722,840
VANGUARD CAPITAL MANAGEMENT LLC	$17.4M	3,715,859

Companies Similar to XFOR

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

OVID

Ovid Therapeutics Inc.

AI score

Very similar · 7 shared holders

BRAIDWELL LP Rosalind Advisors, Inc.Saturn V Capital Management LP

TIL

Instil Bio, Inc.

AI score

Very similar · 1 shared holders

Kalehua Capital Management LLC

IVVD

Invivyd, Inc.

AI score

Similar quality profile · 5 shared holders

PERCEPTIVE ADVISORS LLC BVF INC/IL Saturn V Capital Management LP

CHRS

Coherus Oncology, Inc.

AI score

Similar quality profile · 1 shared holders

Samsara BioCapital, LLC

MYO

MYOMO, INC.

AI score

Similar quality profile · 2 shared holders

Rosalind Advisors, Inc.Palumbo Wealth Management LLC

VRDN

Viridian Therapeutics, Inc.\DE

AI score

Similar quality profile · 5 shared holders

Deep Track Capital, LP PERCEPTIVE ADVISORS LLC VR Adviser, LLC

CAMP

Camp4 Therapeutics Corp

AI score

Similar quality profile · 2 shared holders

Trails Edge Capital Partners, LP Stonepine Capital Management, LLC

KURA

Kura Oncology, Inc.

AI score

Similar quality profile · 4 shared holders

Deep Track Capital, LP BVF INC/IL Rosalind Advisors, Inc.

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put XFOR on your watchlist

Track score changes the day X4 Pharmaceuticals, Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is XFOR a good stock to buy?

13F Pro's AI-powered analysis of X4 Pharmaceuticals, Inc (XFOR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for XFOR are available on the XFOR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. XFOR is classified as a small company.

Which hedge funds own XFOR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling XFOR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of X4 Pharmaceuticals, Inc's investment landscape.